| In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R‐roscovitine) SJ McClue, D Blake, R Clarke, A Cowan, L Cummings, PM Fischer, ... International journal of cancer 102 (5), 463-468, 2002 | 477 | 2002 |
| Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three … Z Nikolovska-Coleska, L Xu, Z Hu, Y Tomita, P Li, PP Roller, R Wang, ... Journal of medicinal chemistry 47 (10), 2430-2440, 2004 | 476 | 2004 |
| Computer automated log P calculations based on an extended group contribution approach G Klopman, JY Li, S Wang, M Dimayuga Journal of Chemical Information and Computer Sciences 34 (4), 752-781, 1994 | 405 | 1994 |
| Chlamydia pneumoniae strain TWAR antibody and angiographically demonstrated coronary artery disease. DH Thom, SP Wang, JT Grayston, DS Siscovick, DK Stewart, RA Kronmal, ... Arteriosclerosis and Thrombosis: A Journal of Vascular Biology 11 (3), 547-551, 1991 | 311 | 1991 |
| Comparability of computer-based and paper-and-pencil testing in K–12 reading assessments: A meta-analysis of testing mode effects S Wang, H Jiao, MJ Young, T Brooks, J Olson Educational and psychological measurement 68 (1), 5-24, 2008 | 297 | 2008 |
| Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology S Wang, PM Fischer Trends in pharmacological sciences 29 (6), 302-313, 2008 | 293 | 2008 |
| Reading and grammar learning through mobile phones S Smith, S Wang University of Hawaii National Foreign Language Resource Center, 2013 | 253 | 2013 |
| Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists S Wang, D Yang, ME Lippman Seminars in oncology 30, 133-142, 2003 | 239 | 2003 |
| Structure–activity relationship of truncated and substituted analogues of the intracellular delivery vector Penetratin PM Fischer, NZ Zhelev, S Wang, JE Melville, R Fåhraeus, DP Lane The Journal of peptide research 55 (2), 163-172, 2000 | 221 | 2000 |
| Cyclin-dependent kinase 2 inhibitors in cancer therapy: an update S Tadesse, EC Caldon, W Tilley, S Wang Journal of medicinal chemistry 62 (9), 4233-4251, 2018 | 205 | 2018 |
| 2-Anilino-4-(thiazol-5-yl) pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity S Wang, C Meades, G Wood, A Osnowski, S Anderson, R Yuill, M Thomas, ... Journal of medicinal chemistry 47 (7), 1662-1675, 2004 | 197 | 2004 |
| National Cancer Institute drug information system 3D database GWA Milne, MC Nicklaus, JS Driscoll, S Wang, D Zaharevitz Journal of chemical information and computer sciences 34 (5), 1219-1224, 1994 | 190 | 1994 |
| Targeting CDK2 in cancer: challenges and opportunities for therapy S Tadesse, AT Anshabo, N Portman, E Lim, W Tilley, CE Caldon, S Wang Drug discovery today 25 (2), 406-413, 2020 | 184 | 2020 |
| A meta-analysis of testing mode effects in grade K-12 mathematics tests S Wang, H Jiao, MJ Young, T Brooks, J Olson Educational and Psychological Measurement 67 (2), 219-238, 2007 | 182 | 2007 |
| Targeting Mnks for cancer therapy J Hou, F Lam, C Proud, S Wang Oncotarget 3 (2), 118, 2012 | 178 | 2012 |
| cIAP1 and cIAP2 limit macrophage necroptosis by inhibiting Rip1 and Rip3 activation S McComb, HH Cheung, RG Korneluk, S Wang, L Krishnan, S Sad Cell Death & Differentiation 19 (11), 1791-1801, 2012 | 172 | 2012 |
| The pleckstrin homology domain proteins Slm1 and Slm2 are required for actin cytoskeleton organization in yeast and bind phosphatidylinositol-4, 5-bisphosphate and TORC2 M Fadri, A Daquinag, S Wang, T Xue, J Kunz Molecular biology of the cell 16 (4), 1883-1900, 2005 | 163 | 2005 |
| Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop SY Wu, I McNae, G Kontopidis, SJ McClue, C McInnes, KJ Stewart, ... Structure 11 (4), 399-410, 2003 | 160 | 2003 |
| Targeting CDK6 in cancer: State of the art and new insights S Tadesse, M Yu, M Kumarasiri, BT Le, S Wang Cell Cycle 14 (20), 3220-3230, 2015 | 143 | 2015 |
| Substituted 4-(thiazol-5-yl)-2-(phenylamino) pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure–activity relationship, and anticancer … H Shao, S Shi, S Huang, AJ Hole, AY Abbas, S Baumli, X Liu, F Lam, ... Journal of medicinal chemistry 56 (3), 640-659, 2013 | 134 | 2013 |
